Pharmaceutical applications of the 3D printing process have recently matured, followed by the FDA approval of Spritam, the first commercial 3D printed dosage form. Due to being a new technology in the conventional dosage formulation field, there is still a dearth of understanding in the 3D printing process regarding the effect of the raw materials on the printed dosage forms and the plausibility of using this technology in dosage development beyond the conventional ways. In this review, the powder-based binder jet 3D printing (BJ3DP) process and its pharmaceutical applications have been discussed, along with a perspective of the formulation development step. The recent applications of BJ3DP in pharmaceutical dosage development, the advantages, and limitations have further been discussed here. A discussion of the critical formulation parameters that need to be explored for the preformulation study of the solid oral dosage development using the BJ3DP process is also presented.

3D 打印工艺的制药应用最近已经成熟，随后 FDA 批准了第一个商业 3D 打印剂型 Spritam。由于3D打印是常规剂型领域的一项新技术，对于3D打印过程中原材料对打印剂型的影响以及将该技术用于超越常规的剂型开发的合理性，目前还缺乏了解。方法。在这篇综述中，讨论了基于粉末的粘合剂喷射 3D 打印 (BJ3DP) 工艺及其制药应用，以及配方开发步骤的观点。BJ3DP 最近在药物剂量开发中的应用、优点和局限性在此进一步讨论。